Clinical trial NCT02140762 - References

Meningococcal Disease — Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Citation(s)

•   Adu-Bobie J, Capecchi B, Serruto D, Rappuoli R, Pizza M
  Two years into reverse vaccinology. Vaccine. 2003 Jan 30;21(7-8):605-10.
•   Bai X, Findlow J, Borrow R
  Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011 Jul;11(7):969-85. doi: 10.1517/14712598.2011.585965. Epub 2011 May 26. Review.

A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.

Details for clinical trial NCT02140762